Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Enios Applications Private Limited Company is currently navigating the patent process with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active case represents the company's current engagement with the USPTO. Such a focused portfolio often indicates a strategic emphasis on a core biotechnological innovation rather than a wide-ranging filing strategy.
The company’s prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. This lack of dispersion means that the company's success in this technology area is currently tied to a single point of review. For the applicant, this creates a simplified environment where the outcome of one negotiation determines the status of the entire pending portfolio. The use of 1 distinct art unit suggests the innovation is technically specialized.
SULLIVAN, DENNIS JOHN is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending action. With the company's active matters assigned to this individual, their specific patterns of allowance and rejection are paramount. Practitioners should focus on the examiner's specific history within the 1 busiest examiner pending workload to anticipate potential hurdles for the pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, DENNIS JOHN | 1 | 57.6% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17282580 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MUCOSAL INFLAMMATORY DISEASES | SULLIVAN, DENNIS JOHN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17282580 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MUCOSAL INFLAMMATORY DISEASES | SULLIVAN, DENNIS JOHN | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17282580 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MUCOSAL INFLAMMATORY DISEASES | SULLIVAN, DENNIS JOHN | 1642 | §102§103 | Non-Final OA | — | Pending | Apr 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEnios Applications Private Limited Company has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dennis John Sullivan has the most, with 1 of Enios Applications Private Limited Company's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
